T7+ Validated with OlinkTM Explore HT: Delivering High-Quality, High-Throughput Proteomics
As of the end of 2025, MGI’s T7+ platform has successfully completed comprehensive verification with OlinkTM Explore HT, the industry’s leading high-throughput proteomics solution. This milestone extends the versatility of MGI’s sequencing ecosystem into next-generation proteomics, offering researchers a powerful, validated workflow for large-scale protein biomarker discovery.
MGI has previously verified the sequencing workflows for different OlinkTM technology libraries on the T7, T1+, and G400 platforms, with data output meeting expectations. This means that customers with different MGI sequencing platforms can now perform high-quality proteomic library sequencing, adding “one more option” for multi-omics research.
| Olink Panel | MGI Sequencing Platform |
|---|---|
| OlinkTM Explore HT | T7+ & T7 |
| OlinkTM Reveal | T1+ & G400 |
Verification at a Glance
The joint validation study systematically evaluated OlinkTM Explore HT performance on T7 and T7+ platforms, benchmarking against established sequencing workflows. The evaluation focused on the consistency of performance, quantitative correlations, assay variability, and detectability.
Result
- Read yield of the Olink Explore HT library on the MGI platform meets expectations and is comparable to the existing Olink technology sequencing workflow: 1 T7+ FCL or 2 T7 FCL can generate the required data volume for Explore HT analysis.
- Data generated from MGI platforms demonstrates high consistency with that from other platforms, while also showing strong intra-platform reproducibility.
- The CV and detectability are comparable across sequencing platforms, ensure reliable protein detection and robust biological insights.
Customer Cases
Based on the aforementioned validation workflow, MGI customers also completed the first sequencing run of OlinkTM Explore HT real-sample libraries on the T7+ platform, with parallel comparison to other validated platforms. This test included 48 Concordance test plasma samples, all of which passed OlinkTM official “Concordance Test.”
Detailed results are summarised as follows:
| Term | Result |
|---|---|
| QC warning | PASS |
| CV | PASS |
| Correlation | PASS (Mean=0.86; Median=0.93) |
| Regression | PASS (0.92) |
| Concordance Test | PASS |
The correlation coefficients for sample Counts (A) and NPX values (B) between the T7+ platform and other platforms are all above 0.99.
The above test results demonstrate that Olink Explore HT performs excellently on MGI’s latest high-throughput sequencing platform, the T7+, delivering high‑quality data and outcomes. This confirms that MGI T7+ provides researchers with a high-throughput proteomics sequencing solution.
Why T7+ for High-Throughput Proteomics?
As MGI’s flagship platform celebrating a decade of innovation, the T7+ seamlessly integrates core technology with the StandardMPS 2.0 sequencing chemistry, redefining the boundaries of large-scale sequencing efficiency through its “quantity and speed, quality and cost-effectiveness” performance.
Supporting flexible loading of 4 flow cells with up to 3.6 Tb output per cell, the T7+ delivers over 14 Tb of high-quality data in just 24 hours in PE150 mode. Designed with intelligence and user-centricity in mind, its compact ~1 m² footprint, 30% reagent reduction, and 50% waste reduction not only minimize operational costs and space requirements but also position it as a powerful yet “warm-hearted” research partner—providing a solid, reliable hardware foundation for diverse applications including large-scale population genomics, deep multi-omics analysis, and clinical-grade sequencing.
